Register to get 1 free article
Reveal the article below by registering for our email newsletter.
Want unlimited access? View Plans
Already have an account? Sign in
Irish veterinary research and development company TriviumVet has announced that it has been acquired by US-based company PBI-Gordon Corporation.
As part of the acquisition, TriviumVet’s portfolio of new animal health therapeutics will now be commercialised in partnership with Pegasus Laboratories.
TriviumVet will remain as an R&D center of excellence growing its team based in the south east of Ireland.
While the financial terms of the deal were not disclosed, it is understood to represent a substantial transaction within the veterinary life sciences sector.
The company has recently received FDA and EMA approvals for a variety of new animal drug therapies including for; feline hypertrophic cardiomyopathy (FDA), treatment of gastrointestinal disease (EMA) and neuropathic pain in dogs (FDA).
Louise Grubb, CEO of TriviumVet, said: “This acquisition is a proud moment for the entire TriviumVet team and for Irish innovation. It validates our vision of building globally relevant veterinary therapeutics from Ireland, and we are excited to see our products reach veterinarians and pet owners worldwide through PBI-Gordon and Pegasus’s commercial strength.”
Steve Clifford, president and CEO of PBI-Gordon, said: “TriviumVet’s pioneering R&D efforts and entrepreneurial spirit align perfectly with our mission to advance animal health. We are delighted to welcome the team to the PBI-Gordon family and look forward to bringing their novel therapies to market.”
The business was founded in Waterford by Louise Grubb and Tom Brennan and specialises in developing therapeutics for companion animals.
